seed
Stage
1
Investors
About
Henlez is an early-stage biotech company developing enzyme-based topical treatments for skin conditions, with a lead pre-clinical program targeting hidradenitis suppurativa (HS), a chronic inflammatory skin disease.
Explore Henlez's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.